XML 84 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8
Asset Contribution Agreement (Tables)
12 Months Ended
Dec. 31, 2013
Asset Contribution Agreement [Abstract]  
Assets Transferred by BioTime and Related Consideration
The assets transferred by BioTime and the related consideration paid were recorded as follows:

Consideration transferred to BioTime:
 
 
Asterias Series B shares
 
$
52,164,568
 
Warrants to purchase Asterias Series B shares
  
2,012,481
 
Excess of contributed assets’ value over consideration
  
4,800,063
 
Total consideration issued
 
$
58,977,112
 
 
    
Assets transferred by BioTime:
    
BioTime common shares, at fair value
 
$
34,985,163
 
BioTime Warrants, at fair value
  
18,276,406
 
Cancellation of outstanding obligation to BioTime
  
5,000,000
 
Investment in affiliates, at cost
  
415,543
 
Geron asset acquisition related transaction costs paid by BioTime
  
300,000
 
Total assets transferred
 
$
58,977,112
 
Assets Acquired from Geron and Related Consideration
The assets acquired from Geron and the related consideration were recorded as follows:

Consideration paid to Geron:
 
 
Asterias Series A shares, net of share issuance costs of $541,800
 
$
15,121,222
 
Obligation to distribute BioTime Warrants
  
18,276,406
 
Transaction and other costs
  
1,519,904
 
Total consideration paid
 
$
34,917,532
 
Assets acquired from Geron (preliminary allocation):
    
 Patents and other intellectual property rights related to hES cells
 
$
29,017,009
 
Deferred tax liability arising from difference in book versus tax basis on Geron intangible assets acquired
(11,558,243)
 IPR&D expensed upon acquisition
  
17,458,766
 
Total assets and in-process research and development acquired
 
$
34,917,532